Lee Agnes Y Y
Thrombosis Program, University of British Columbia and Vancouver Coastal Health, Vancouver, British Columbia, Canada.
J Clin Oncol. 2009 Oct 10;27(29):4895-901. doi: 10.1200/JCO.2009.22.3958. Epub 2009 Sep 8.
Cancer-associated thrombosis is a frequent and costly complication in patients with cancer. Significant morbidity and mortality not only result from thrombotic events, but may also occur as a result of the therapeutic interventions. The established treatment for cancer-associated thrombosis is anticoagulant therapy. Of the few options available, low molecular weight heparin (LMWH) is the preferred agent because of its efficacy, safety, and convenience. Alternatives to LMWH have undesirable limitations and have demonstrated poorer efficacy and safety in the oncology population. Treatment of recurrent thrombosis, patients with concurrent bleeding issues, role of vena cava filter insertion, and duration of therapy are all areas in need of urgent research. Treatment of cancer-associated thrombosis remains a challenging task and is limited by the paucity of evidence-based data. Research is urgently needed to advance current practice and improve patient care.
癌症相关血栓形成是癌症患者中常见且代价高昂的并发症。严重的发病率和死亡率不仅源于血栓事件，也可能是治疗干预的结果。癌症相关血栓形成的既定治疗方法是抗凝治疗。在现有的几种选择中，低分子量肝素（LMWH）因其有效性、安全性和便利性而成为首选药物。LMWH的替代药物存在不良局限性，并且在肿瘤患者中已证明疗效和安全性较差。复发性血栓形成的治疗、合并出血问题的患者、下腔静脉滤器植入的作用以及治疗持续时间都是急需研究的领域。癌症相关血栓形成的治疗仍然是一项具有挑战性的任务，并且受到循证数据匮乏的限制。迫切需要开展研究以改进当前的治疗方法并改善患者护理。
